NEK2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL182613	0.51	7/20
SCHEMBL182614	0.51	7/20
SCHEMBL231766	0.79	6/20
SCHEMBL182322	0.50	6/20
SCHEMBL182323	0.50	6/20
SCHEMBL234334	1.00	5/20
SCHEMBL232042	1.00	4/20
SCHEMBL233442	0.75	4/20
SCHEMBL147422	0.66	4/20
SCHEMBL239605	0.55	4/20
SCHEMBL95142	1.00	3/20
SCHEMBL264158	0.79	3/20
SCHEMBL94964	0.79	3/20
SCHEMBL146263	0.71	3/20
SCHEMBL171201	0.69	3/20
SCHEMBL146734	0.67	3/20
SCHEMBL144651	0.67	3/20
SCHEMBL145902	0.67	3/20
SCHEMBL146677	0.67	3/20
SCHEMBL144785	0.67	3/20

Clinical trials — most relevant to NEK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	PHASE2	COMPLETED
Abemaciclib With or Without Atezolizumab for mCRPC	PHASE2	COMPLETED
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	PHASE2	COMPLETED
Doxycycline in Human Pulmonary Tuberculosis	PHASE2	COMPLETED
A Study of Revumenib and Mezigdomide in People With Leukemia	PHASE1/PHASE2	RECRUITING
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy	PHASE1	RECRUITING
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	PHASE1	COMPLETED
Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer	PHASE1	ACTIVE_NOT_RECRUITING
Intravenous Immune Globulin to Treat Hereditary Inclusion Body Myopathy	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
The Roles of Neutrophil Elastase in Lung Cancer	nan	UNKNOWN
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients	nan	RECRUITING
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors	nan	ACTIVE_NOT_RECRUITING
Genetics of Neonatal Encephalopathy and Related Disorders	nan	RECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib	nan	COMPLETED
Implementing Patients´ Competence in Oral Breast Cancer Therapy	nan	UNKNOWN
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study	nan	COMPLETED
Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma	nan	COMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC	nan	UNKNOWN
The Relation of Microtubule-Associated Protein 2 and Cell Migration	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a NEK2 binder may also engage these)

Protein	Name	Similarity
O35942	—	0.997	O35942 →
P62205	—	0.982	P62205 →
O54785	—	0.978	O54785 →
Q91821	—	0.977	Q91821 →
Q28GW8	—	0.977	Q28GW8 →
P47809	—	0.977	P47809 →
MAP2K4	Dual specificity mitogen-activated protein kinase kinase 4	0.976	landscape →
LIMK2	LIM domain kinase 2	0.976	landscape →
MAPKAPK5	MAP kinase-activated protein kinase 5	0.975	landscape →
O54863	—	0.975	O54863 →
Q9R012	—	0.973	Q9R012 →
PLK2	Serine/threonine-protein kinase PLK2	0.973	landscape →
Q61241	—	0.973	Q61241 →
MELK	Maternal embryonic leucine zipper kinase	0.973	landscape →
P53351	—	0.972	P53351 →
CHEK2	Serine/threonine-protein kinase Chk2	0.972	landscape →
Q5R4L1	—	0.972	Q5R4L1 →
P49187	—	0.972	P49187 →
Q5E9L6	—	0.972	Q5E9L6 →
A4K2M3	—	0.971	A4K2M3 →
MAP4K5	Mitogen-activated protein kinase kinase kinase kinase 5	0.971	landscape →
Q9Z265	—	0.971	Q9Z265 →
F1QGZ6	—	0.971	F1QGZ6 →
O54992	—	0.971	O54992 →
Q32L23	—	0.971	Q32L23 →
Q2TA25	—	0.971	Q2TA25 →
MOK	MAPK/MAK/MRK overlapping kinase	0.971	landscape →
Q3SZW1	—	0.971	Q3SZW1 →
TBK1	Serine/threonine-protein kinase TBK1	0.971	landscape →
MAP3K5	Mitogen-activated protein kinase kinase kinase 5	0.971	landscape →